Pei Nie

Dr. Pei Nie


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
LSLizhi Shao
Lizhi Shao
CLChao Liang
Chao Liang
YYYe Yan
Ye Yan
HZHaibin Zhu
Haibin Zhu
XJXiaoming Jiang
Xiaoming Jiang
SRShancheng Ren
Shancheng Ren

17 January 2024 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
QLQiyuan Li
Qiyuan Li
NWNing Wang
Ning Wang
YWYanmei Wang
Yanmei Wang
XLXiaoli Li
Xiaoli Li
QSQiushi Su
Qiushi Su
PNPei Nie
Pei Nie
Objective: To evaluate the efficacy of the CT-based intratumoral, peritumoral, and combined radiomics signatures in predicting progression-free survival (PFS) of patients with chondrosarcoma (CS). Methods: In this study, patients diagnosed with CS between January 2009 and January 2022 were retrospectively screened, and 214 patients with CS from two centers were respectively enrolled into the training cohorts (institution 1, n = 113) and test cohorts (institution 2, n = 101). The intratumoral and peritumoral radiomics features were extracted from CT images. The intratumoral, peritumoral, and combined radiomics signatures were constructed respectively, and their radiomics scores (Rad-score) were calculated. The performance of intratumoral, peritumoral, and combined radiomics signatures in PFS prediction in patients with CS was evaluated by C-index, time-dependent area under the receiver operating characteristics curve (time-AUC), and time-dependent C-index (time C-index). Results: Eleven, 7, and 16 features were used to construct the intratumoral, peritumoral, and combined radiomics signatures, respectively. The combined radiomics signature showed the best prediction ability in the training cohort (C-index, 0.835; 95%; confidence interval [CI], 0.764–0.905) and the test cohort (C-index, 0.800; 95% CI, 0.681–0.920). Time-AUC and time C-index showed that the combined signature outperformed the intratumoral and peritumoral radiomics signatures in the prediction of PFS. Conclusion: The CT-based combined signature incorporating intratumoral and peritumoral radiomics features can predict PFS in patients with CS, which might assist clinicians in selecting individualized surveillance and treatment plans for CS patients. Critical relevance statement: Develop and validate CT-based intratumoral, peritumoral, and combined radiomics signatures to evaluate the efficacy in predicting prognosis of patients with CS. Key points: • Reliable prognostic models for preoperative chondrosarcoma are lacking. • Combined radiomics signature incorporating intratumoral and peritumoral features can predict progression-free survival in patients with chondrosarcoma. • Combined radiomics signature may facilitate individualized stratification and management of patients with chondrosarcoma. Graphical

11 April 2024 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
XLXiaoli Li
Xiaoli Li
XSXianglong Shi
Xianglong Shi
YWYanmei Wang
Yanmei Wang
JPJing Pang
Jing Pang
XZXia Zhao
Xia Zhao
PNPei Nie
Pei Nie
Objective: The preoperative identification of tumor grade in chondrosarcoma (CS) is crucial for devising effective treatment strategies and predicting outcomes. The study aims to build and validate a CT-based radiomics nomogram (RN) for the preoperative identification of tumor grade in CS, and to evaluate the correlation between the RN-predicted tumor grade and postoperative outcome. Methods: A total of 196 patients (139 in the training cohort and 57 in the external validation cohort) were derived from three different centers. A clinical model, radiomics signature (RS) and RN (which combines significant clinical factors and RS) were developed and validated to assess their ability to distinguish low-grade from high-grade CS with area under the curve (AUC). Additionally, Kaplan-Meier survival analysis was applied to examine the association between RN-predicted tumor grade and recurrence-free survival (RFS) of CS. The predictive accuracy of the RN was evaluated using Harrell’s concordance index (C-index), hazard ratio (HR) and AUC. Results: Size, endosteal scalloping and active periostitis were selected to build the clinical model. Three radiomics features, based on CT images, were selected to construct the RS. Both the RN (AUC, 0.842) and RS (AUC, 0.835) were superior to the clinical model (AUC, 0.776) in the validation set (P = 0.003, 0.040, respectively). A correlation between Nomogram score (Nomo-score, derived from RN) and RFS was observed through Kaplan-Meier survival analysis in the training and test cohorts (log-rank P < 0.050). Patients with high Nomo-score tumors were 2.669 times more likely to suffer recurrence than those with low Nomo-score tumors (HR, 2.669, P < 0.001). Conclusions: The CT-based RN performed well in predicting both the histologic grade and outcome of CS.

2 February 2024 in European Journal of Radiology
Verified
Journal Article
Closed access
QSQiushi Su
Qiushi Su
NWNing Wang
Ning Wang
BWBingyan Wang
Bingyan Wang
YWYanmei Wang
Yanmei Wang
ZDZhengjun Dai
Zhengjun Dai
PNPei Nie
Pei Nie

28 July 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
JGJia Guo
Jia Guo
JMJianguo Miao
Jianguo Miao
WSWeikai Sun
Weikai Sun
YLYanlei Li
Yanlei Li
PNPei Nie
Pei Nie
WXWenjian Xu
Wenjian Xu
Accurate prediction of bone metastasis-free survival (BMFS) after complete surgical resection in patients with non-small cell lung cancer (NSCLC) may facilitate appropriate follow-up planning. The aim of this study was to establish and validate a preoperative CT-based deep learning (DL) signature to predict BMFS in NSCLC patients. We performed a retrospective analysis of 1547 NSCLC patients who underwent complete surgical resection, followed by at least 36 months of monitoring at two hospitals. We constructed a DL signature from multiparametric CT images using 3D convolutional neural networks, and we integrated this signature with clinical-imaging factors to establish a deep learning clinical-imaging signature (DLCS). We evaluated performance using Harrell’s concordance index (C-index) and the time-dependent receiver operating characteristic. We also assessed the risk of bone metastasis (BM) in NSCLC patients at different clinical stages using DLCS. The DL signature successfully predicted BM, with C-indexes of 0.799 and 0.818 for the validation cohorts. DLCS outperformed the DL signature with corresponding C-indexes of 0.806 and 0.834. Ranges for area under the curve at 1, 2, and 3 years were 0.820–0.865 for internal and 0.860–0.884 for external validation cohorts. Furthermore, DLCS successfully stratified patients with different clinical stages of NSCLC as high- and low-risk groups for BM (p < 0.05). CT-based DL can predict BMFS in NSCLC patients undergoing complete surgical resection, and may assist in the assessment of BM risk for patients at different clinical stages.

9 May 2025 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
KZKaiyue Zhi
Kaiyue Zhi
YWYanmei Wang
Yanmei Wang
LYLei Yan
Lei Yan
FHFeng Hou
Feng Hou
JWJie Wu
Jie Wu
PNPei Nie
Pei Nie
Objectives: To develop and validate an interpretable CT-based vision transformer (ViT) model for preoperative prediction of the stage, size, grade, and necrosis (SSIGN) and outcome in clear cell renal cell carcinoma (ccRCC) patients. Methods: Eight hundred forty-five ccRCC patients from multiple centers were retrospectively enrolled. For each patient, 768 ViT features were extracted in the cortical medullary phase (CMP) and renal parenchymal phase (RPP) images, respectively. The CMP ViT model (CVM), RPP ViT model (RVM), and CMP-RPP combined ViT model (CRVM) were constructed to predict the SSIGN in ccRCC patients. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of each model. Decision curve analysis (DCA) was used to evaluate the net clinical benefit. The endpoint was the progression-free survival (PFS). Kaplan–Meier survival analysis was used to assess the association between model-predicted SSIGN and PFS. The SHAP approach was applied to determine the prediction process of the CRVM. Results: The CVM, RVM, and CRVM demonstrated good performance in predicting SSIGN, with a high AUC of 0.859, 0.883, and 0.895, respectively, in the test cohort. DCA demonstrated the CRVM performed best in clinical net benefit. In predicting PFS, CRVM achieved a higher Harrell’s concordance index (C-index, 0.840) than the CVM (0.719) and RVM (0.773) in the test cohort. The SHAP helped us understand the impact of ViT features on CRVM’s SSIGN prediction from a global and individual perspective. Conclusion: The interpretable CT-based CRVM may serve as a non-invasive biomarker in predicting the SSIGN and outcome of ccRCC. Critical relevance statement: Our findings outline the potential of an interpretable CT-based ViT biomarker for predicting the SSIGN score and outcome of ccRCC, which might facilitate patient counseling and assist clinicians in therapy decision-making for individual cases. Key Points: Current first-line imaging lacks preoperative prediction of the SSIGN score for ccRCC patients. The ViT model could predict the SSIGN score and outcome of ccRCC patients. This study can facilitate the development of personalized treatment for ccRCC patients. Graphical